The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Open accessAbstract
Recent clinical trials revealed the impressive efficacy of immunological checkpoint blockade in different types of metastatic cancers. Such data underscore that immunotherapy is one of the most promising strategies for cancer treatment. In addition, preclinical studies provide evidence that some cytotoxic drugs have the ability to stimulate the immune system, resulting in anti-tumor immune responses that contribute to clinical efficacy of these agents. These observations raise the hypothesis that the next step for cancer treatment is the combination of cytotoxic agents and immunotherapies. The present review aims to summarize the immune-mediated effects of chemotherapeutic agents and their clinical relevance, the biological and clinical features of immune checkpoint blockers and finally, the preclinical and clinical rationale for novel therapeutic strategies combining anticancer agents and immune checkpoint blockers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedImproved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni1009 · Cited by 1,830
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Self-citationDewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Self-citationGhiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Self-citationImmunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Self-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
Zeng, R., Spolski, R., Finkelstein, S. E., Oh, S., Kovanen, P. E., Hinrichs, C. S., Pise-Masison, C. A., Radonovich, M. F., Brady, J. N., Restifo, N. P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041057 · Cited by 727
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 564
Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 559
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Kalos, M., & June, C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.002 · Cited by 486
Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity
Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485
Chakraborty, M., Abrams, S. I., Camphausen, K., Liu, K., Scott, T., Coleman, C. N., & Hodge, J. W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6338 · Cited by 467
Schadendorf, D., Ugurel, S., Schuler-Thurner, B., Nestle, F. O., Enk, A., Bröcker, E.-B., Grabbe, S., Rittgen, W., Edler, L., Sucker, A., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj138 · Cited by 467
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Hinrichs, C. S., Spolski, R., Paulos, C. M., Gattinoni, L., Kerstann, K. W., Palmer, D. C., Klebanoff, C. A., Rosenberg, S. A., Leonard, W. J., & Restifo, N. P. (2008) · Blood · doi:10.1182/blood-2007-09-113050 · Cited by 462
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435
Combining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 375
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y.-X., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 359
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE
Mitchison, N. A. (1955) · The Journal of Experimental Medicine · doi:10.1084/jem.102.2.157 · Cited by 326
Workshop R: Tumor Immunology, Abstract R1 bis R30
(2001) · Immunobiology · doi:10.1016/s0171-2985(04)70018-2 · Cited by 312
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Disis, M. L., Wallace, D. R., Gooley, T. A., Dang, Y., Slota, M., Lu, H., Coveler, A. L., Childs, J. S., Higgins, D. M., Fintak, P. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6789 · Cited by 300
The convergence of radiation and immunogenic cell death signaling pathways
Golden, E. B., Pellicciotta, I., Demaria, S., Barcellos-Hoff, M. H., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00088 · Cited by 282
Verbrugge, I., Hagekyriakou, J., Sharp, L. L., Galli, M., West, A., McLaughlin, N. M., Duret, H., Yagita, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275
Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination
Wheeler, C. J., Das, A., Liu, G., Yu, J. S., & Black, K. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0497 · Cited by 266
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
(1979) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/63.5.1229 · Cited by 263
Excess Cancers Among HIV-Infected People in the United States
Robbins, H. A., Pfeiffer, R. M., Shiels, M. S., Li, J., Hall, H. I., & Engels, E. A. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju503 · Cited by 262
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Brignone, C., Gutierrez, M., Mefti, F., Brain, E., Jarcau, R., Cvitkovic, F., Bousetta, N., Medioni, J., Gligorov, J., Grygar, C., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-71 · Cited by 255
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239
The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells
Végran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F., Rébé, C., Dérangère, V., Ryffel, B., et al. (2014) · Nature Immunology · doi:10.1038/ni.2925 · Cited by 228
Self-citationBrignone, C., Escudier, B., Grygar, C., Marcu, M., & Triebel, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0068 · Cited by 226
In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang, G., Tschoi, M., Spolski, R. J., Lou, Y., Ozaki, K., Feng, C., Kim, G., Leonard, W. J., & Hwu, P. (2003) · PubMed · Cited by 221
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Zhang, L., Dermawan, K., Jin, M., Liu, R., Zheng, H., Xu, L., Zhang, Y., Cai, Y., Chu, Y., & Xiong, S. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.013 · Cited by 209
Cancer Vaccines: Moving Beyond Current Paradigms
Schlom, J., Arlen, P. M., & Gulley, J. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0588 · Cited by 207
Ko, H.-J., Kim, Y.-J., Kim, Y.-S., Chang, W.-S., Ko, S.-Y., Chang, S.-Y., Sakaguchi, S., & Kang, C.-Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4639 · Cited by 203
Vonderheide, R. H., Burg, J. M., Mick, R., Trosko, J. A., Li, D., Shaik, M. N., Tolcher, A. W., & Hamid, O. (2013) · OncoImmunology · doi:10.4161/onci.23033 · Cited by 202
Ganss, R., Ryschich, E., Klar, E., Arnold, B., & Hämmerling, G. J. (2002) · UWA Profiles and Research Repository (UWA) · Cited by 200
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
Chi, K.-H., Liu, S.-J., Li, C.-P., Kuo, H.-P., Wang, Y.-S., Chao, Y., & Hsieh, S.-L. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000154248.74383.5e · Cited by 187
The Yin and Yang of T Cell Costimulation
Allison, J. P., & Krummel, M. F. (1995) · Science · doi:10.1126/science.270.5238.932 · Cited by 180
Role of T lymphocytes in tumor response to radiotherapy
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00095 · Cited by 174
Trial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 173
Javeed, A., Ashraf, M., Riaz, A., Ghafoor, A., Afzal, S., & Mukhtar, M. M. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.08.009 · Cited by 172
Trial watch: Peptide vaccines in cancer therapy
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22428 · Cited by 171
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 170
Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Ménard, C., Martin, F., Apetoh, L., Bouyer, F., & Ghiringhelli, F. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0505-6 · Cited by 167
Self-citationWimmers, F., Schreibelt, G., Sköld, A. E., Figdor, C. G., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00165 · Cited by 166
Newcomb, E. W., Demaria, S., Lukyanov, Y., Shao, Y., Schnee, T., Kawashima, N., Lan, L., Dewyngaert, J. K., Zagzag, D., McBride, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0593 · Cited by 166
Larmonier, N., Janikashvili, N., LaCasse, C. J., Larmonier, C. B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B., & Katsanis, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6955 · Cited by 160
Weiner, H. L., & Cohen, J. A. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms790oa · Cited by 158
Consensus nomenclature for CD8+T cell phenotypes in cancer
Apétoh, L., Smyth, M. J., Drake, C. G., Abastado, J., Apte, R. N., Ayyoub, M., Blay, J., Bonneville, M., Butterfield, L. H., Caignard, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.998538 · Cited by 156
Self-citationHistone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity
Nencioni, A., Beck, J., Werth, D., Grünebach, F., Patrone, F., Ballestrero, A., & Brossart, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2903 · Cited by 156
Matsumoto, S., Batra, S., Saito, K., Yasui, H., Choudhuri, R., Gadisetti, C., Subramanian, S., Devasahayam, N., Munasinghe, J., Mitchell, J. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2025 · Cited by 137
Wolf, A. M., Wolf, D. G. F., Rumpold, H. F., Ludwiczek, S., Enrich, B., Gastl, G. A., Weiß, G., & Tilg, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501758102 · Cited by 136
Kong, Y.-C. M., & Flynn, J. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00206 · Cited by 135
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
Petrella, T. M., Tozer, R. G., Bélanger, K., Savage, K. J. J., Wong, R., Smylie, M., Kamel‐Reid, S., Tron, V. A., Chen, B. E., Hunder, N. N. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0655 · Cited by 135
Norell, H., Poschke, I. C., Charo, J., Wei, W. Z., Erskine, C. L., Piechocki, M. P., Knutson, K. L., Bergh, J. C. S., Lidbrink, E. K., & Kiessling, R. W. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-53 · Cited by 127
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Galluzzi, L., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 126
Benavides, L. C., Gates, J. D., Carmichael, M. G., Patel, R. S., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Craig, D., Stojadinovic, A., Ponniah, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1126 · Cited by 121
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 119
Trial Watch: Peptide vaccines in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26621 · Cited by 119
Tong, Y., Song, W., & Crystal, R. G. (2001) · PubMed · Cited by 118
Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response
Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 115
Lechleider, R. J., Arlen, P. M., Tsang, K.-Y., Steinberg, S. M., Yokokawa, J., Cereda, V., Camphausen, K. A., Schlom, J., Dahut, W. L., & Gulley, J. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5162 · Cited by 106
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
Nisticò, P., Capone, I., Palermo, B., Bello, D. D., Ferraresi, V., Moschella, F., Aricò, E., Valentini, M., Bracci, L., Cognetti, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23886 · Cited by 105
Yu, B., Kusmartsev, S. A., Cheng, F., Paolini, M., Nefedova, Y., Sotomayor, E. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 104
Negative Regulation of T-Cell Function by PD-1
Zha, Y. Y., Blank, C. A., & Gajewski, T. F. (2004) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v24.i4.10 · Cited by 101
Trial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 100
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Scholten, P. E. T., Reijm, M., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1330-5 · Cited by 97
Demaria, S., Pilones, K. A., Vanpouille‐Box, C., Golden, E. B., & Formenti, S. C. (2014) · Radiation Research · doi:10.1667/rr13500.1 · Cited by 95
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 94
Trial Watch: Toll-like receptor agonists in oncological indications
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 85
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
Milani, A., Sangiolo, D., Montemurro, F., Aglietta, M., & Valabrega, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt133 · Cited by 83
Yang, S., & Haluska, F. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4599 · Cited by 77
Apétoh, L., Végran, F., Ladoire, S., & Ghiringhelli, F. (2011) · Current Molecular Medicine · doi:10.2174/156652411795976574 · Cited by 75
Self-citationKwek, S. S., Dao, V. A., Roy, R., Hou, Y., Alajajian, D., Simko, J. P., Small, E. J., & Fong, L. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201529 · Cited by 74
Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 72
Perna, S. K., Angelis, B. D., Pagliara, D., Hasan, S. T., Zhang, L., Mahendravada, A., Heslop, H. E., Brenner, M. K., Rooney, C. M., Dotti, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2143 · Cited by 72
Millward, M., Underhill, C. R., Lobb, S., McBurnie, J., Meech, S. J., Gómez-Navarro, J., Marshall, M. A., Huang, B., & Mather, C. B. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.227 · Cited by 68
Trial watch: Immunostimulatory cytokines in cancer therapy
Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.29030 · Cited by 65
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 63
Cancer treatment: the combination of vaccination with other therapies
Andersen, M. H., Sørensen, R. B., Schrama, D., Svane, I. M., Becker, J. C., & Straten, P. T. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0480-y · Cited by 61
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24850 · Cited by 58
Enhancing the anticancer effects of 5-fluorouracil: Current challenges and future perspectives
Apétoh, L., & Ghiringhelli, F. (2014) · Biomedical Journal · doi:10.4103/2319-4170.130923 · Cited by 56
Self-citationImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
Li, S., & Liu, Y. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s46199 · Cited by 46
Perforin-mediated suppression of B-cell lymphoma
Bolitho, P., Street, S. E. A., Westwood, J. A., Edelmann, W., MacGregor, D. P., Waring, P., Murray, W. K., Godfrey, D. I., Trapani, J. A., Johnstone, R. W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809008106 · Cited by 46
Triozzi, P. L., Aldrich, W. A., Achberger, S., Ponnazhagan, S., Alcazar, O., & Saunthararajah, Y. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1204-x · Cited by 38
Sherrill, B. H., Wang, J., Kotapati, S., & Chin, K. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.298 · Cited by 30
Update on the role of ipilimumab in melanoma and first data on new combination therapies
Maio, M., Giacomo, A. M. D., Robert, C., & Eggermont, A. M. M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835dae4f · Cited by 30
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu342.5 · Cited by 23
Shin, M., Moon, H. H., Kim, J. M., Park, J. B., Kwon, C. H. D., Kim, S.-J., & Joh, J. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.08.061 · Cited by 12
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.015 · Cited by 631
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Chemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
Metadata
- Authors
- Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 26
- Issue
- 9
- Pages
- 1813-1823
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W1971821333
- Cited by
- 280
- References
- 164
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.